Guardant Health Inc

Guardant Health Inc Stock Forecast & Price Prediction

Live Guardant Health Inc Stock (GH) Price
$22.66

7

Ratings

  • Buy 7
  • Hold 0
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$22.66

P/E Ratio

-3.54

Volume Traded Today

$1.3M

Dividend

Dividends not available for GH

52 Week High/low

41.06/20.67

Guardant Health Inc Market Cap

$2.77B

🛑 Alert: These ten stocks could have higher potential than $GH 🛑

Before you buy GH you’ll want to see this list of ten stocks that have huge potential. Want to see if GH made the cut? Enter your email below

GH Summary

From what 7 stock analysts predict, the share price for Guardant Health Inc (GH) might increase by 97.97% in the next year. This is based on a 12-month average estimation for GH. Price targets go from $37.00 to $54.00. The majority of stock analysts believe GH is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

GH Analyst Ratings

Guardant Health Inc has a total of 7 Wall St Analyst ratings. There are 7 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Guardant Health Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

GH stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

matthew sykes
Goldman Sachs

Buy

$37.0

maintained

Jan 29, 2024
alexander nowak
Craig-Hallum

Buy

$54.0

maintained

Jan 9, 2024
daniel arias
Stifel Nicolaus

Buy

$45.0

maintained

Jan 9, 2024
kyle mikson cfa
Canaccord Genuity

Buy

$50.0

maintained

Jan 8, 2024
puneet souda
Leerink Partners

Buy

None

maintained

Jan 8, 2024
derik de bruin
Bank of America Securities

Buy

$38.0

maintained

Jan 8, 2024
mark massaro
BTIG

Buy

$50.0

maintained

Jan 1, 2024
david westenberg
Piper Sandler

Buy

$40.0

rated

Dec 20, 2023
doug schenkel
Wolfe Research

Hold

None

initiatedcoverage

Dec 12, 2023
andrew cooper
Raymond James

Buy

$27.0

upgraded

Nov 13, 2023
tejas savant
Morgan Stanley

Buy

$50.0

maintained

Nov 7, 2023
sung ji nam
Scotiabank

Buy

$47.0

reiterated

Nov 7, 2023
daniel brennan
TD Cowen

Buy

$44.0

reiterated

Nov 6, 2023
patrick b donnelly
Citi

Buy

$50.0

maintained

Oct 2, 2023
eve burstein
Bernstein

Buy

$34.0

initiatedcoverage

Sep 28, 2023
rachel vatnsdal
J.P. Morgan

Buy

$60.0

maintained

Aug 4, 2023
dan leonard
Credit Suisse

Buy

$55.0

maintained

May 10, 2023
max masucci
Cowen & Co.

Buy

$53.0

maintained

Feb 24, 2023
julia qin
J.P. Morgan

Buy

$65.0

maintained

Feb 24, 2023
mason carrico
Stephens

Buy

$63.0

reiterated

Feb 16, 2023

GH Company Information

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

GH
Guardant Health Inc (GH)

When did it IPO

2018

Staff Count

1,793

Country

United States

Sector/Industry

Healthcare/Diagnostics & Research

CEO

Dr. Helmy Eltoukhy Ph.D.

Market Cap

$2.77B

Guardant Health Inc (GH) Financial Data

In 2023, GH generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that GH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

N/A

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year

Revenue From 2023

N/A

0.00 %
From Previous Year
  • Revenue TTM $535.8M
  • Operating Margin TTM -79.0%
  • Gross profit TTM $293.2M
  • Return on assets TTM -18.5%
  • Return on equity TTM -218.9%
  • Profit Margin -80.7%
  • Book Value Per Share 1.94%
  • Market capitalisation $2.77B
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • Revenue for 2023 N/A
  • EPS this year (TTM) $-4.03

Guardant Health Inc (GH) Latest News

... ...

Similar Stocks to Guardant Health Inc - GH

🛑 Alert: These ten stocks could have higher potential than $GH 🛑

Before you buy GH you’ll want to see this list of ten stocks that have huge potential. Want to see if GH made the cut? Enter your email below

...

GH Frequently asked questions

The highest forecasted price for GH is $54.00 from alexander nowak at Craig-Hallum.

The lowest forecasted price for GH is $37.00 from matthew sykes from Goldman Sachs

The GH analyst ratings consensus are 7 buy ratings, 0 hold ratings, and 0 sell ratings.